Biomea Fusion, Inc. (BMEA) Dividend History

Company News

• Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

  Biomea Fusion presented new data on its investigational diabetes drug icovamenib at the ADA conference, highlighting its potential to enhance glycemic control and promote weight loss when combined with GLP-1 therapies, while preserving lean mass.

  GlobeNewswire Inc.
• Biomea Fusion Announces Proposed Public Offering of Securities

  Biomea Fusion, a clinical-stage diabetes and obesity company, announced a proposed public offering of its common stock and warrants. The offering is subject to market conditions and is expected to close on or around June 20, 2025.

  Benzinga
• Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

  Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.

  Zacks Investment Research

  Featured Companies: ADMA AGEN PBYI
• Why Biomea Fusion Stock Crushed It This Week

  A promising data readout in type 2 diabetes lit a fire underneath the biotech's stock this week.

  The Motley Fool
• Lululemon and Micron shares surge, UBS’s stock rallies on CEO reinstatement and other stocks on the move

  Here are some of the biggest U.S. stock price movers on Wednesday as markets rallied on improved investor sentiment about banking sector health.

  MarketWatch

  Featured Companies: AFRM BBWI HOOD LULU MU SQ SSYS UBS